Joincare Pharmaceutical Group Industry Co (SHSE:600380) Piotroski F-Score: 6 (As of Aug. 12, 2026) — Near Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600380 Joincare Pharmaceutical Group Industry Co Ltd SHSE:600380
80 GF Score
Price ¥10.49
GF Value ¥11.11
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Joincare Pharmaceutical Group Industry Co Piotroski F-Score?

Joincare Pharmaceutical Group Industry Co SHSE:600380 +1.65% 80 Piotroski F-Score is 6 as of Aug. 12, 2026, which is at its 10-year median of 6.00. GuruFocus rates SHSE:600380 with a GF Score™ of 80/100 and a GF Value™ of ¥11.11 (Fairly Valued). The stock has 3 warning signs investors should review. Among 976 Drug Manufacturers companies, Joincare Pharmaceutical Group Industry Co ranks better than 78.69% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Joincare Pharmaceutical Group Industry Co has an F-score of 6 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Joincare Pharmaceutical Group Industry Co's Piotroski F-Score or its related term are showing as below:

SHSE:600380' s Piotroski F-Score Range Over the Past 10 Years
Min: 4   Med: 6   Max: 8
Current: 6

During the past 13 years, the highest Piotroski F-Score of Joincare Pharmaceutical Group Industry Co was 8. The lowest was 4. And the median was 6.

Joincare Pharmaceutical Group Industry Co  (SHSE:600380) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Joincare Pharmaceutical Group Industry Co Piotroski F-Score Related Terms


Joincare Pharmaceutical Group Industry Co Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Joincare Pharmaceutical Group Industry Co's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Joincare Pharmaceutical Group Industry Co Piotroski F-Score Chart

Joincare Pharmaceutical Group Industry Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.00 5.00 6.00 7.00 5.00

Joincare Pharmaceutical Group Industry Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.00 5.00 5.00 5.00 6.00

SHSE:600380 vs ZTS: Piotroski F-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Joincare Pharmaceutical Group Industry Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Joincare Pharmaceutical Group Industry Co Piotroski F-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Joincare Pharmaceutical Group Industry Co's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Joincare Pharmaceutical Group Industry Co's Piotroski F-Score falls into.


SHSE:600380
80GF Score
Joincare Pharmaceutical Group Industry Co Ltd SHSE:600380
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was 349.152 + 306.274 + 244.334 + 414.971 = ¥1,315 Mil.
Cash Flow from Operations was 1116.417 + 1075.045 + 890.441 + 914.648 = ¥3,997 Mil.
Revenue was 3809.049 + 3579.479 + 3737.932 + 3721.498 = ¥14,848 Mil.
Gross Profit was 2382.332 + 2309.663 + 2278.557 + 2351.583 = ¥9,322 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(35768.906 + 35552.215 + 36013.653 + 35414.299 + 35477.299) / 5 = ¥35645.2744 Mil.
Total Assets at the begining of this year (Mar25) was ¥35,769 Mil.
Long-Term Debt & Capital Lease Obligation was ¥1,003 Mil.
Total Current Assets was ¥22,151 Mil.
Total Current Liabilities was ¥9,356 Mil.
Net Income was 336.626 + 335.136 + 275.01 + 435.788 = ¥1,383 Mil.

Revenue was 3894.82 + 3664.195 + 3720.651 + 4089.279 = ¥15,369 Mil.
Gross Profit was 2462.309 + 2291.402 + 2286.718 + 2530.863 = ¥9,571 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(36462.147 + 36496.077 + 36172.5 + 35718.129 + 35768.906) / 5 = ¥36123.5518 Mil.
Total Assets at the begining of last year (Mar24) was ¥36,462 Mil.
Long-Term Debt & Capital Lease Obligation was ¥2,562 Mil.
Total Current Assets was ¥23,038 Mil.
Total Current Liabilities was ¥8,770 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Joincare Pharmaceutical Group Industry Co's current Net Income (TTM) was 1,315. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Joincare Pharmaceutical Group Industry Co's current Cash Flow from Operations (TTM) was 3,997. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=1314.731/35768.906
=0.03675625

ROA (Last Year)=Net Income/Total Assets (Mar24)
=1382.56/36462.147
=0.03791768

Joincare Pharmaceutical Group Industry Co's return on assets of this year was 0.03675625. Joincare Pharmaceutical Group Industry Co's return on assets of last year was 0.03791768. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Joincare Pharmaceutical Group Industry Co's current Net Income (TTM) was 1,315. Joincare Pharmaceutical Group Industry Co's current Cash Flow from Operations (TTM) was 3,997. ==> 3,997 > 1,315 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=1002.705/35645.2744
=0.0281301

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=2561.973/36123.5518
=0.07092251

Joincare Pharmaceutical Group Industry Co's gearing of this year was 0.0281301. Joincare Pharmaceutical Group Industry Co's gearing of last year was 0.07092251. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=22150.504/9355.984
=2.36752265

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=23037.766/8769.73
=2.62696411

Joincare Pharmaceutical Group Industry Co's current ratio of this year was 2.36752265. Joincare Pharmaceutical Group Industry Co's current ratio of last year was 2.62696411. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Joincare Pharmaceutical Group Industry Co's number of shares in issue this year was 1804.223. Joincare Pharmaceutical Group Industry Co's number of shares in issue last year was 1894.732. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=9322.135/14847.958
=0.62783953

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=9571.292/15368.945
=0.62276832

Joincare Pharmaceutical Group Industry Co's gross margin of this year was 0.62783953. Joincare Pharmaceutical Group Industry Co's gross margin of last year was 0.62276832. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=14847.958/35768.906
=0.41510797

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=15368.945/36462.147
=0.42150411

Joincare Pharmaceutical Group Industry Co's asset turnover of this year was 0.41510797. Joincare Pharmaceutical Group Industry Co's asset turnover of last year was 0.42150411. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+0+1+1+0+1+1+0
=6

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Joincare Pharmaceutical Group Industry Co has an F-score of 6 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 6 mean?
Joincare Pharmaceutical Group Industry Co (SHSE:600380) has a Piotroski F-Score of 6 as of Aug. 12, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Joincare Pharmaceutical Group Industry Co and its competitors. This is near median its historical median of 6.00. Over the past decade, Joincare Pharmaceutical Group Industry Co's Piotroski F-Score has ranged from 4.00 to 8.00. According to the industry distribution chart, Joincare Pharmaceutical Group Industry Co ranks #208 out of 976 companies in the Drug Manufacturers industry, placing it in the top 21.3%.
Is Joincare Pharmaceutical Group Industry Co's Piotroski F-Score too high?
Joincare Pharmaceutical Group Industry Co's current Piotroski F-Score of 6 is near median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 4.00 to a high of 8.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. Joincare Pharmaceutical Group Industry Co's value of 6 is 20% above this industry median. Based on the distribution chart, Joincare Pharmaceutical Group Industry Co ranks #208 out of 976 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Joincare Pharmaceutical Group Industry Co has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Joincare Pharmaceutical Group Industry Co's Piotroski F-Score compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Joincare Pharmaceutical Group Industry Co ranks #208 out of 976 companies for Piotroski F-Score. This places Joincare Pharmaceutical Group Industry Co in the top 21% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 5.00. Joincare Pharmaceutical Group Industry Co's value of 6 is 20% above this benchmark. Historically, Joincare Pharmaceutical Group Industry Co's own Piotroski F-Score has ranged from 4.00 to 8.00 over the past decade. While the company's 10-year median is 6.00 vs. the industry median of 5.00, Joincare Pharmaceutical Group Industry Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 976 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Joincare Pharmaceutical Group Industry Co's current Piotroski F-Score of 6 is 20% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Joincare Pharmaceutical Group Industry Co and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Joincare Pharmaceutical Group Industry Co's current Piotroski F-Score is 6, which is near median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Joincare Pharmaceutical Group Industry Co stock overvalued right now?
Based on GuruFocus' analysis, Joincare Pharmaceutical Group Industry Co (SHSE:600380) is currently considered Fairly Valued. The stock's GF Value™ is ¥11.11, compared to a current price of ¥10.49 — trading 5.6% below its estimated fair value. The current Piotroski F-Score is 6, which is near median its 10-year median of 6.00 and 20% above the Drug Manufacturers industry median of 5.00. Joincare Pharmaceutical Group Industry Co's overall GF Score™ is 80/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Joincare Pharmaceutical Group Industry Co (SHSE:600380), the current Piotroski F-Score is 6 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Joincare Pharmaceutical Group Industry Co (SHSE:600380) Overvalued in 2026?

Based on GuruFocus' analysis, Joincare Pharmaceutical Group Industry Co stock appears to be undervalued. The current stock price of ¥10.49 is trading 5.6% below its estimated GF Value™ of ¥11.11. GuruFocus considers Joincare Pharmaceutical Group Industry Co to be Fairly Valued.

Key valuation signals for SHSE:600380:

  • Piotroski F-Score: 6 (near median its 10-year median of 6.00)
  • GF Value™: ¥11.11 vs. price of ¥10.49 (5.6% below fair value)
  • GF Score™: 80/100 with 3 warning signs
  • Industry Position: 20% above the Drug Manufacturers median (#208 of 976)

No single metric tells the full story. See the SHSE:600380 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Joincare Pharmaceutical Group Industry Co Business Description

Address No. 17, Langshan Road, North District, High-tech Zone, Nanshan District, Guangdong, Shenzhen, CHN, 518057
Joincare Pharmaceutical Group Industry Co Ltd is an integrated pharmaceutical company, the business scope covers healthcare products, APIs, final dosage forms, prescription drugs, OTCs, Chinese traditional medicine, chemical drugs, and testing agents. APIs are antibiotic series and their intermediates 7ACA, 4AA and F9. Prescription drugs focus on the realms of the digestive tract, a blood vessel of heart and brain, infection, tumor, nervous cerebrovascular section, urinary system etc. OTCs include gastrointestinal drug Dele-Livzon, Live Bifidobacterium Preparation, oral ulcer drugs Yiketie, cold medicine Antiviral Oral Granule, External use skin medicine.
80GF Score

Get the complete analysis for SHSE:600380

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥10.49
Price
¥11.11
GF Value